Use of semaglutide after acute coronary syndrome: an exploratory retrospective study - PubMed
3 days ago
- #acute coronary syndrome
- #type 2 diabetes mellitus
- #semaglutide
- Semaglutide, a GLP-1 receptor agonist, was studied for its use post-acute coronary syndrome (ACS) in patients with type 2 diabetes mellitus (T2DM).
- The study was a retrospective, multicenter observational study involving 60 patients discharged with semaglutide after ACS.
- At the first follow-up (108 ± 39 days), 81% of patients remained on semaglutide, with discontinuations mainly due to gastrointestinal intolerance (15%).
- Significant improvements were observed in body weight (-4.7 ± 1.6 kg), BMI (-1.7 ± 0.6 kg/m²), and HbA1c (from 64.3 ± 18.2 to 49.6 ± 10.4 mmol/mol).
- At the second follow-up (278 ± 60 days), 97.4% of the remaining patients were still on semaglutide, with further weight loss (-2.6 ± 3.8 kg) and HbA1c reduction (40.5 ± 18.6 mmol/mol).
- No cardiovascular events, renal decline, or pancreatic events were reported during the study period.
- The study concluded that initiating semaglutide post-ACS is feasible, well-tolerated, and associated with high persistence and early cardiometabolic improvements.